Document is current

Article History

Received: 7 May 2023

Revised: 8 November 2023

Accepted: 24 November 2023

First Online: 3 January 2024

Declarations

:

: C.S. received research funding from Böhringer Ingelheim, Ingelheim, Germany. All other authors declare that they have no competing interests.

: The study protocol involving human tissue samples was approved by the responsible Ethics Committee of the Medical Faculty of Heidelberg University (Germany; S-017/2013) and was conducted in accordance with the 1964 Declaration of Helsinki. Human induced pluripotent stem cell (hiPSC) line UMGi014-C clone 14 (isWT1.14) was derived from dermal fibroblasts of a healthy male donor and experimental protocols were approved by the ethics committee of the University Medical Center Göttingen (10/9/15). All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals adopted by the US National Institutes of Health (NIH publication No. 86–23, revised 1985), with EU Directive 2010/63/EU, with the current version of the German Law on the Protection of Animals, and the ARRIVE guidelines. The study protocol was approved by the local Animal Welfare Committee (Regierungspräsidium Karlsruhe, Germany, reference numbers G-165/19; G-67/20; G-229/21).

: Written informed consent was obtained from all individual participants included in the study.